Accessibility Menu
Molecular Partners Ag logo

Molecular Partners Ag(NASDAQ) MOLN

Market Cap$154.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-79%
5 Year-79%
1 Year+19%
1 Month+3%
$4.10
-1.44%
-0.06Today
Molecular Partners Ag last closing stock price
MetricPriceDate
Last closeUSD 4.132026-08-12
Molecular Partners Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.72%USD 4.162026-08-05
1 month+3%USD 4.012026-07-13
3 month+7.55%USD 3.842026-05-14
Year to date-5.24%USD 4.362025-12-31
1 year+19.02%USD 3.472025-08-12
3 year-31.62%USD 6.042023-08-11
5 year-78.67%USD 19.362021-08-13
Since inception-78.98%USD 19.652021-06-16

Molecular Partners Ag Financials at a Glance

Market Cap

$154.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 0.00

Net Income (TTM)

-CHF 64.16M

EPS (TTM)

-$1.93

P/E Ratio

-2.14

Dividend

$0.00

Beta (Volatility)

0.53 (Low)

Price

$4.10

Volume

16

Open

$4.13

Previous Close

$4.13

Daily Range

$4.13 - $4.13

52-Week Range

$3.46 - $5.36

Estimated Earnings Date

Aug 25, 2026

MOLN News

Arrow up, blocks

3 Stocks That Have Soared as the Market Sank: Are They Buys Now?

Keith SpeightsJan 28, 2022
A researcher studying a sample in a petri dish

Why Molecular Partners Stock Crushed the Market Today

Eric VolkmanJan 10, 2022

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Molecular Partners Ag

Molecular Partners AG is a clinical-stage biopharmaceutical company focused on developing innovative therapeutic proteins. The company specializes in its proprietary DARPin® technology, which is utilized in various product candidates targeting significant medical needs.

Products and Services
  • Abicipar: A DARPin therapeutic in Phase III trials for eye diseases
  • MP0420: A multi-specific DARPin targeting SARS-CoV-2 for COVID-19
  • MP0310: An immuno-oncology candidate in Phase Ia trials
Growth Outlook
  • Strong pipeline with multiple candidates in advanced clinical stages
  • Partnerships with major pharmaceutical companies enhance development capabilities
  • Focus on high-demand therapeutic areas like oncology and infectious diseases
Financial Highlights
  • Cash and short-term investments of approximately $78.5 million as of Q1 2026
  • Operating loss of $13.1 million reported in Q1 2026
  • Current ratio of 9.42 indicates strong liquidity position
Molecular Partners AG operates in the biotechnology sector, leveraging its unique DARPin® technology to address unmet medical needs. The company has a robust pipeline, including candidates for eye diseases, COVID-19, and various cancers, which positions it well for future growth. Recent partnerships with established pharmaceutical companies further strengthen its market presence and development capabilities. Financially, the company maintains a solid liquidity position, with significant cash reserves to support ongoing research and development efforts. Despite reporting operating losses, the focus on high-demand therapeutic areas and innovative solutions may attract investor interest in the company's long-term potential.
AI Generated • Aug 1, 2026

Industry

Biotechnology

Sector

Health Care

Employees

149

CEO

Patrick Amstutz, PhD

Website

www.molecularpartners.com

Headquarters

Schlieren, ZH 8952, CH

MOLN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-66.19%

Return on Capital

-69.21%

Return on Assets

-66.25%

Earnings Yield

-46.73%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$154.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

37.51M

Volume

16

Avg. Volume

5.66K

Financials (TTM)

Gross Profit

-CHF 10.75M

Operating Income

-CHF 61.52M

EBITDA

-CHF 61.93M

Operating Cash Flow

-CHF 53.80M

Capital Expenditure

-CHF 333.55K

Free Cash Flow

-CHF 54.13M

Cash & ST Invst.

CHF 78.53M

Total Debt

CHF 3.33M

Molecular Partners Ag Performance Analysis

Molecular Partners Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 198,520,4951760.8%
20232023-12-31CHF 7,831,732-96.1%
20242024-12-31CHF 5,643,446-27.9%
20252025-12-31CHF 0N/A
Molecular Partners Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Molecular Partners Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF 3.71N/A
20232023-12-31CHF -2.10N/A
20242024-12-31CHF -1.80-14.3%
20252025-12-31CHF -1.9910.5%
Molecular Partners Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-22.2%
Q32025-09-3041.8%
Q42025-12-31-3.1%
Q12026-03-31-6.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CHF 0.00

N/A

Gross Profit

-CHF 9.45M

-1438.2%

Gross Margin

0.00%

N/A

Market Cap

$154.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.16M

N/A

Employees

134

N/A

Net Income

-CHF 13.14M

+29.5%

EBITDA

-CHF 12.64M

+27.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CHF 78.53M

-40.0%

Total Debt

CHF 3.33M

+55.7%

Accounts Receivable

CHF 2.31M

-42.0%

Inventory

CHF 0.00

N/A

Long Term Debt

CHF 2.13M

+131.2%

Short Term Debt

CHF 1.21M

-1.0%

Return on Assets

-66.25%

N/A

Return on Invested Capital

-70.20%

N/A

Free Cash Flow

-CHF 14.47M

+17.5%

Operating Cash Flow

-CHF 14.47M

+15.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MISTMilestone Pharmaceuticals Inc.
$1.13-11.42%
NKTXNkarta, Inc.
$2.39+2.58%
CRBPCorbus Pharmaceuticals Holdings, Inc.
$9.76+2.63%
PEPGPepGen Inc.
$2.90+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$146.15+0.10%
SMCISuper Micro Computer
$37.61+0.19%
INTCIntel
$100.95+0.03%
NOKNokia
$10.32+0.09%

Questions About MOLN

What is the current price of Molecular Partners Ag?

Molecular Partners Ag is trading at $4.13 per share.

What is the 52-week range for Molecular Partners Ag?

Over the past 52 weeks, Molecular Partners Ag has traded between $3.46 and $5.36.

How much debt does Molecular Partners Ag have?

As of the most recent reporting period, Molecular Partners Ag reported total debt of CHF 4.16M.

How much cash does Molecular Partners Ag have on hand?

Molecular Partners Ag reported CHF 98.03M in cash and cash equivalents in its most recent financial results.

What is Molecular Partners Ag’s dividend yield?

Molecular Partners Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services